Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade.
about
High systemic levels of low-density lipoprotein cholesterol: fuel to the flames in inflammatory osteoarthritis?Nutraceuticals: potential for chondroprotection and molecular targeting of osteoarthritisA current review of molecular mechanisms regarding osteoarthritis and painTNF Accelerates Death of Mandibular Condyle Chondrocytes in Rats with Biomechanical Stimulation-Induced Temporomandibular Joint DiseaseImmunopathogenesis of osteoarthritisComparative evaluation of the effects of platelet‑rich plasma formulations on extracellular matrix formation and the NF‑κB signaling pathway in human articular chondrocytesTransforming growth factor activating kinase 1 regulates extracellular matrix degrading enzymes and pain-related molecule expression following tumor necrosis factor-α stimulation of synovial cells: an in vitro study.Arthritis and pain. Future targets to control osteoarthritis painCytokines as biochemical markers for knee osteoarthritis.The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritisTargeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee.Advantages of Pure Platelet-Rich Plasma Compared with Leukocyte- and Platelet-Rich Plasma in Treating Rabbit Knee Osteoarthritis.The future of osteoarthritis therapeutics: emerging biological therapy.Joint injury and osteoarthritis: soluble mediators in the course and treatment of cartilage pathology.Are we moving in the right direction with osteoarthritis drug discovery?Biologic agents in osteoarthritis: hopes and disappointments.Ion channels and osteoarthritic pain: potential for novel analgesics.Mechanically induced experimental knee osteoarthritis benefits from anti-inflammatory and immunomodulatory properties of simvastatin via inhibition of matrix metalloproteinase-3Obesity and osteoarthritis, more than just wear and tear: pivotal roles for inflamed adipose tissue and dyslipidaemia in obesity-induced osteoarthritis.The role of innate immunity in osteoarthritis: when our first line of defense goes on the offensive.New discovery rarely runs smooth: an update on progranulin/TNFR interactionsThe role of progranulin in arthritis.In vivo luminescence imaging of NF-κB activity and serum cytokine levels predict pain sensitivities in a rodent model of osteoarthritis.Does progranulin account for the opposite effects of etanercept and infliximab/adalimumab in osteoarthritis?: Comment on Olson et al.: "Therapeutic Opportunities to Prevent Post-Traumatic Arthritis: Lessons From the Natural History of Arthritis AfteP2X3 and P2X2/3 Receptors Play a Crucial Role in Articular Hyperalgesia Development Through Inflammatory Mechanisms in the Knee Joint Experimental Synovitis.Current biological understanding and futuristic views for osteoarthritis treatment: Optimistic or otherwise?Macrophages and bone inflammation.The anatomical basis for a novel classification of osteoarthritis and allied disorders.CD11c(+) macrophages and levels of TNF-α and MMP-3 are increased in synovial and adipose tissues of osteoarthritic mice with hyperlipidaemia.
P2860
Q26800733-D9170658-3AAE-4071-8C31-101AA0D51E86Q26860861-3E17CBA4-7FFF-426B-A1EA-CA4A8AE92242Q27023006-3C7847B2-BA41-4333-B345-9AB11CFD7EC1Q27348546-2E5299C1-9428-49B9-9800-7D9B928A4DF2Q33587966-BC874781-CE58-4EF4-BCFA-FB207C8E7D8EQ33672274-FED5358C-7C0B-4DF1-B825-AB4A9BC4BC02Q33861852-FD778FC5-658E-4ECA-9E4E-BEE024F885ACQ34636446-43FE794E-1B48-4CE2-A69D-F766648C00A2Q35003515-D588BBD9-2568-495F-82B3-3F27668819A6Q35630135-6DA5EB8C-B188-4FFA-9F56-61AA7BE2AA60Q36633149-898DBB45-EB8A-43EC-AFC2-2FBE1523A538Q36816671-79FC6878-2F44-4283-9927-7EA610D86612Q37333939-E1240E91-8283-4711-915D-F4EB253F37BFQ37773271-796CCFE8-CF6A-408F-A9FD-BC7B24AEB013Q37956680-6FB00720-6B6D-4829-ABF1-4F61300EB99EQ38094906-D73118FC-5CE5-477A-8345-B50286FAC57DQ38160393-C66D02E5-16D7-4316-A4C0-1B42765D31CBQ38270933-59699D16-B1E1-4245-8D0B-7E35070FE6DCQ38287819-CAA7F846-7DFA-47A4-A929-C675D5B22CEAQ38320224-D7AC70DC-E3FC-41FB-814C-2FE4DC7B1E4EQ38593074-15856418-19F7-45F1-B279-89FD7386636AQ38922852-BBD6789E-4877-4D64-9107-DF9E647999B6Q38949744-3D2A1986-45BB-4BD5-BD90-A46F9740F5F5Q42680109-FD2801C6-FE69-45BE-A2E0-BE165F848107Q47987127-D397CAE2-773C-4078-A205-B61005E7AC33Q48165446-95FF02C6-B6D0-4AF7-B0CD-936926A62944Q52584284-8402AA51-5510-4D63-8AE7-F40802036224Q52848337-406CCB2B-E4E4-4C6F-B94E-03773C05A5A6Q53604587-DCB1BEEA-360F-48AD-924A-57A473352A40
P2860
Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Successful treatment of inflam ...... mour necrosis factor blockade.
@en
Successful treatment of inflam ...... mour necrosis factor blockade.
@nl
type
label
Successful treatment of inflam ...... mour necrosis factor blockade.
@en
Successful treatment of inflam ...... mour necrosis factor blockade.
@nl
prefLabel
Successful treatment of inflam ...... mour necrosis factor blockade.
@en
Successful treatment of inflam ...... mour necrosis factor blockade.
@nl
P2860
P921
P356
P1476
Successful treatment of inflam ...... mour necrosis factor blockade.
@en
P2093
H Schulze-Koops
P2860
P304
P356
10.1136/ARD.2006.053272
P407
P577
2006-04-01T00:00:00Z